Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SCCL
MCID: SML038
MIFTS: 69

Small Cell Cancer of the Lung (SCCL)

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Small Cell Cancer of the Lung

About this section

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung 58
Small Cell Lung Cancer 77 54 60 38 30 56 6
Lung Small Cell Carcinoma 12 54 15
Small Cell Lung Carcinoma 45 17
Sclc 58 60
Small Cell Neuroendocrine Carcinoma of the Lung 54
Small Cell Carcinoma of Lung 74
Small-Cell Cancer of Lung 58
Cancer, Lung, Small Cell 41
Carcinoma, Small Cell 74
Oat Cell Lung Cancer 54
Sclc; Sccl 58
Sclc1 58
Sccl 58

Characteristics:

Orphanet epidemiological data:

60
small cell lung cancer
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
small cell cancer of the lung:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:5409
OMIM 58 182280
KEGG 38 H00013
MeSH 45 D055752
NCIt 51 C4917
ICD10 via Orphanet 35 C34.9
UMLS via Orphanet 75 C0149925
Orphanet 60 ORPHA70573
MedGen 43 C0149925
SNOMED-CT via HPO 70 126713003 263681008
Sources

Summaries for Small Cell Cancer of the Lung

About this section
Disease Ontology : 12 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells and is located in the lung.

MalaCards based summary : Small Cell Cancer of the Lung, also known as small cell lung cancer, is related to lung cancer susceptibility 3 and small cell carcinoma of the bladder. An important gene associated with Small Cell Cancer of the Lung is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Small cell lung cancer and MicroRNAs in cancer. The drugs Cisplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are neoplasm of the lung and behavior/neurological

Wikipedia : 77 Small-cell carcinoma (also known as small-cell lung cancer, or oat-cell carcinoma) is a type of highly... more...

Description from OMIM: 182280
Sources

Related Diseases for Small Cell Cancer of the Lung

About this section

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 679)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 33.1 AKT1 HOTAIR MALAT1 PIK3CA TP53 TUG1
2 small cell carcinoma of the bladder 32.8 CHGA ENO2 SYP
3 lung cancer 32.0 TUG1 TP73 TP53 TOP1 SYP RB1
4 retinoblastoma 31.6 HOTAIR MALAT1 RB1 TP53
5 small cell carcinoma 31.0 CHGA ENO2 PTEN SYP TP53
6 lung squamous cell carcinoma 31.0 AKT1 CCAT2 PIK3CA PTEN TP53 TUG1
7 transitional cell carcinoma 30.9 ENO2 PTEN TP53
8 breast cancer 30.9 AKT1 CCAT2 HOTAIR HOTTIP MALAT1 MIR21
9 glioma 30.8 TP53 PTEN PIK3CA MIR21 MALAT1 HOTTIP
10 pulmonary large cell neuroendocrine carcinoma 30.7 CHGA ENO2 SYP
11 estrogen-receptor positive breast cancer 30.7 AKT1 PIK3CA TP53
12 renal cell carcinoma, papillary, 1 30.7 PIK3CA PTEN TP53
13 squamous cell carcinoma, head and neck 30.7 AKT1 HOTAIR MIR21 PIK3CA PTEN RB1
14 carcinosarcoma 30.7 PIK3CA PTEN TP53
15 kidney cancer 30.7 HOTAIR MALAT1 MIR21 TP53
16 colorectal cancer 30.7 AKT1 CCAT2 HOTAIR HOTTIP MALAT1 MIR21
17 glioblastoma multiforme 30.6 AKT1 MIR21 PIK3CA PTEN RB1 TP53
18 gastrointestinal stromal tumor 30.6 TP53 SYP PTEN HOTAIR ENO2 CHGA
19 large cell carcinoma 30.6 CHGA ENO2 SYP
20 suppression of tumorigenicity 12 30.6 TP53 PTEN PIK3CA GRPR CHGA AKT1
21 stroke, ischemic 30.6 AKT1 ENO2 MALAT1 PIK3CA
22 b-cell lymphomas 30.6 HOTAIR MALAT1 TP53 TUG1
23 pheochromocytoma 30.5 CHGA ENO2 POMC SST SYP
24 neuroblastoma 30.5 AKT1 ENO2 HOTAIR MALAT1 PIK3CA TP53
25 ovarian cancer 30.5 AKT1 CCAT2 HOTAIR MALAT1 MIR21 PIK3CA
26 large cell neuroendocrine carcinoma 30.5 CHGA ENO2 SYP
27 glioblastoma 30.5 TUG1 TP53 RB1 PTEN PIK3CA MIR21
28 carcinoid syndrome 30.4 CHGA ENO2 SST SYP
29 pancreatic cancer 30.4 AKT1 HOTAIR HOTTIP MALAT1 MIR21 PIK3CA
30 neuroendocrine tumor 30.4 CHGA ENO2 SST SYP
31 olfactory neuroblastoma 30.4 CHGA ENO2 SYP
32 paraganglioma 30.4 CHGA ENO2 SST SYP
33 myeloma, multiple 30.4 AKT1 HOTAIR MALAT1 TP53 TUG1
34 adenocarcinoma 30.4 AKT1 MALAT1 PIK3CA PTEN RB1 TP53
35 hemangioma 30.4 CHGA ENO2 PTEN SYP
36 esophageal cancer 30.4 TP53 RB1 PTEN PIK3CA MIR21 MALAT1
37 ectopic cushing syndrome 30.4 POMC SST SYP
38 merkel cell carcinoma 30.4 CHGA ENO2 SST SYP TP53
39 clear cell renal cell carcinoma 30.3 CCAT2 MALAT1 MIR21 PTEN TP53 TUG1
40 gastric adenocarcinoma 30.3 AKT1 CHGA HOTAIR PIK3CA PTEN TP53
41 thyroid carcinoma, familial medullary 30.3 CHGA ENO2 MALAT1 POMC SST
42 leukemia, acute myeloid 30.3 AKT1 HOTAIR MALAT1 MIR21 TP53 TUG1
43 ovarian cancer 1 30.3 AKT1 PIK3CA TP53
44 meningioma, familial 30.3 AKT1 ENO2 PTEN SST SYP TP53
45 bladder cancer 30.3 CCAT2 HOTAIR MALAT1 MIR21 RB1 TP53
46 gastric cancer 30.2 AKT1 CCAT2 HOTAIR HOTTIP MALAT1 MIR21
47 osteogenic sarcoma 30.2 TUG1 TP53 RB1 MALAT1 HOTTIP HOTAIR
48 malignant glioma 30.2 HOTAIR HOTTIP TUG1
49 hepatocellular carcinoma 30.2 AKT1 CCAT2 HOTAIR HOTTIP MALAT1 MIR21
50 squamous cell carcinoma 30.1 TUG1 TP53 RB1 PTEN PIK3CA MALAT1

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:



Diseases related to Small Cell Cancer of the Lung
Sources

Symptoms & Phenotypes for Small Cell Cancer of the Lung

About this section

Human phenotypes related to Small Cell Cancer of the Lung:

33
# Description HPO Frequency HPO Source Accession
1 neoplasm of the lung 33 HP:0100526

Symptoms via clinical synopsis from OMIM:

58
Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy

Clinical features from OMIM:

182280

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 AKT1 ENO2 GRPR PIK3CA POMC PTEN
2 neoplasm MP:0002006 9.5 AKT1 PIK3CA POMC PTEN RB1 TP53
3 nervous system MP:0003631 9.36 AKT1 CHGA ENO2 PIK3CA POMC PTEN
Sources

Drugs & Therapeutics for Small Cell Cancer of the Lung

About this section

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 469)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
4
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
5
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
6
Dopamine Approved Phase 4,Phase 3,Phase 2 62-31-7, 51-61-6 681
7
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
8
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
9 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
17 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
18 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2
19 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
22 Dopamine Agents Phase 4,Phase 3,Phase 2
23 Antidepressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Cholinergic Agents Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Central Nervous System Stimulants Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Nicotinic Agonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
29
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
33
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
34
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
35
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
36
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
37
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 123948-87-8, 119413-54-6 60700
38
Dalteparin Approved Phase 3 9005-49-6
39
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 772 46507594
40
Mesna Approved, Investigational Phase 3 3375-50-6 598
41
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
42
Vinorelbine Approved, Investigational Phase 3,Phase 1,Phase 2 71486-22-1 60780 44424639
43
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
44
Enoxaparin Approved Phase 3,Phase 2 9005-49-6 772
45
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 216974-75-3
46
Ipilimumab Approved Phase 3,Phase 2,Phase 1 477202-00-9
47
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
48
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
49
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
50
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 864)
# Name Status NCT ID Phase Drugs
1 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride Not yet recruiting NCT03890055 Phase 4 Anlotinib Hydrochloride
5 the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) Not yet recruiting NCT03264794 Phase 4 Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial;Gefitinib tablets (Yi Ruisha），First medication;Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
6 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4 Icotinib
7 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3 cisplatin;etoposide;cisplatin;etoposide
8 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
9 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3 cisplatin;cyclophosphamide;epirubicin hydrochloride;etoposide
10 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
11 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;paclitaxel
12 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3 carboplatin;epirubicin hydrochloride;etoposide;etoposide phosphate;ifosfamide;paclitaxel
13 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
14 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3 Carboplatin;Palifosfamide-tris;Etoposide;Carboplatin
15 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3 picoplatin
16 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3 Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
17 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
18 SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
19 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
20 A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer Completed NCT00717938 Phase 3 cisplatinum or carboplatin and e.g.etoposide.;cisplatinum or carboplatin and e.g.etoposide+enoxaparin
21 Bevacizumab in Extensive Small Cell Lung Cancer Completed NCT00930891 Phase 2, Phase 3 Standard Chemotherapy (PCDE or PE);Experimental Treatment (PCDE or PE + bevacizumab);Prerandomization Chemotherapy (PCDE or PE)
22 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
23 Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer Completed NCT01125995 Phase 3
24 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed NCT01450761 Phase 3 Etoposide;Cisplatin;Carboplatin
25 Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer Completed NCT00003011 Phase 3 marimastat;Placebo
26 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Completed NCT00119613 Phase 3 placebo;darbepoetin alfa
27 Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults Completed NCT00043927 Phase 3 topotecan/cisplatin;etoposide/cisplatin
28 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Completed NCT00143455 Phase 3 Etoposide + cisplatin;Irinotecan + cisplatin
29 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed NCT00363415 Phase 3 pemetrexed;etoposide;carboplatin
30 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3 Cisplatin + etoposide;Epirubicin + ifosfamide + etoposide
31 Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer Completed NCT00003364 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
32 Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00003299 Phase 3 cisplatin;etoposide;paclitaxel
33 Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00006352 Phase 3
34 Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission Completed NCT00005062 Phase 3
35 Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer Completed NCT00061919 Phase 3 Carboplatin, etoposide & thalidomide;Carboplatin, etoposide & placebo
36 Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed NCT00006349 Phase 3 donepezil hydrochloride
37 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3 cisplatin;etoposide;irinotecan hydrochloride
38 Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00003279 Phase 3
39 Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Completed NCT00016211 Phase 3
40 Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer Completed NCT00002822 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
41 Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer Completed NCT00003917 Phase 3 topotecan hydrochloride
42 A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
43 Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Completed NCT00320359 Phase 3 Intravenous topotecan/cisplatin;Intravenous etoposide/cisplatin
44 Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
45 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00041015 Phase 3 cisplatin;etoposide;topotecan hydrochloride
46 A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer Completed NCT00349492 Phase 3 IP
47 Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer Completed NCT00433498 Phase 3 carboplatin;cisplatin;etoposide phosphate;pravastatin sodium
48 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed NCT00660504 Phase 3 Amrubicin Hydrochloride;Etoposide-Cisplatin combined chemotherapy
49 Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide Completed NCT00290953 Phase 2, Phase 3 SR48692
50 Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Completed NCT00276276 Phase 3 topotecan

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: small cell lung carcinoma

Sources

Genetic Tests for Small Cell Cancer of the Lung

About this section

Genetic tests related to Small Cell Cancer of the Lung:

# Genetic test Affiliating Genes
1 Small Cell Lung Cancer 30 RB1
Sources

Anatomical Context for Small Cell Cancer of the Lung

About this section

MalaCards organs/tissues related to Small Cell Cancer of the Lung:

42
Lung, Brain, Lymph Node, Endothelial, Bone, Prostate, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Small Cell Cancer of the Lung:

20
The Lung
Sources

Publications for Small Cell Cancer of the Lung

About this section

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 13510)
# Title Authors Year
1
Acromegaly associated with GIST, non-small cell lung cancer, clear cell renal cancer, myeloma multiplex, medulla oblongata tumor, adrenal adenoma and follicular thyroid nodules. ( 30742299 )
2019
2
Diagnosis of Combined Adenocarcinoma Small Cell Lung Cancer By Endobronchial Ultrasound Transbronchial Needle Aspiration. ( 30908396 )
2019
3
The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer. ( 30896637 )
2019
4
Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma. ( 30900377 )
2019
5
Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma. ( 30799776 )
2019
6
Impact of different image reconstructions on PET quantification in non-small cell lung cancer: a comparison of adenocarcinoma and squamous cell carcinoma. ( 30673302 )
2019
7
Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma. ( 30642444 )
2019
8
Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. ( 30680206 )
2019
9
A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer. ( 30799393 )
2019
10
Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. ( 30906559 )
2019
11
Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis. ( 30706684 )
2019
12
Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. ( 30850565 )
2019
13
Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy. ( 30591500 )
2019
14
Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer. ( 30813149 )
2019
15
lncRNA BCAR4 Increases Viability, Invasion, and Migration of Non-Small Cell Lung Cancer Cells by Targeting Glioma-Associated Oncogene 2 (GLI2). ( 29615150 )
2019
16
Granulomatosis with polyangiitis in a patient with biopsy-proven IgG4-related pulmonary disease and coincident small cell lung cancer. ( 30872335 )
2019
17
Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. ( 30828042 )
2019
18
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. ( 29621875 )
2019
19
HIF-1α and NF-κB play important roles in regulating PD-L1 expression by EGFR mutants in non-small cell lung cancer cells. ( 30844110 )
2019
20
Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. ( 30736829 )
2019
21
Nm23-H1 inhibits hypoxia induced epithelial-mesenchymal transition and stemness in non-small cell lung cancer cells. ( 30763256 )
2019
22
PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data. ( 30797490 )
2019
23
Blocking OLFM4/HIF-1α axis alleviates hypoxia-induced invasion, epithelial-mesenchymal transition, and chemotherapy resistance in non-small-cell lung cancer. ( 30680718 )
2019
24
Chloramphenicol Induces Autophagy and Inhibits the Hypoxia Inducible Factor-1 Alpha Pathway in Non-Small Cell Lung Cancer Cells. ( 30609861 )
2019
25
Hypoxia-sensitive LINC01436 is regulated by E2F6 and acts as an oncogene by targeting miR-30a-3p in non-small cell lung cancer. ( 30614188 )
2019
26
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. ( 30762084 )
2019
27
Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab. ( 30775040 )
2019
28
Therapy-related acute myeloid leukemia after chemotherapy in extensive disease-small cell lung cancer. ( 30656018 )
2019
29
Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non-small cell lung cancer. ( 30902468 )
2019
30
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study. ( 30902613 )
2019
31
Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells. ( 30902795 )
2019
32
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. ( 30902917 )
2019
33
Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. ( 30903517 )
2019
34
Predictive importance of galectin-3 for recurrence of non-small cell lung cancer. ( 30903521 )
2019
35
Co-mutations in EGFR driven non-small cell lung cancer. ( 30904603 )
2019
36
Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer. ( 30905203 )
2019
37
Spectral CT and its specific values in the staging of patients with non-small cell lung cancer: technical possibilities and clinical impact. ( 30905380 )
2019
38
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). ( 30905617 )
2019
39
Unforeseen N2 disease following negative endosonography with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: a systematic review and meta-analysis. ( 30905829 )
2019
40
Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells. ( 30906213 )
2019
41
The positive feedback loop of lncRNA DANCR/miR-138/Sox4 facilitates malignancy in non-small cell lung cancer. ( 30906628 )
2019
42
MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4/E2F1 in non-small cell lung cancer. ( 30906631 )
2019
43
Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer. ( 30906637 )
2019
44
CSF-1R regulates non-small cell lung cancer cells dissemination through Wnt3a signaling [Retraction]. ( 30906644 )
2019
45
Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer. ( 30906765 )
2019
46
Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer ( 30909672 )
2019
47
Correction to: Are there differences among operators in false-negative rates of endosonography with needle aspiration for mediastinal nodal staging of non-small cell lung cancer? ( 30909918 )
2019
48
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. ( 30910574 )
2019
49
Redefining treatment paradigms in first-line advanced non-small cell lung cancer. ( 30910855 )
2019
50
TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription. ( 30911072 )
2019
Sources

Variations for Small Cell Cancer of the Lung

About this section

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

6 (show top 50) (show all 200)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
2 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
3 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
4 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
5 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh38 Chromosome 17, 7673764: 7673764
6 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
7 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
8 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
9 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
10 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
11 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
12 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh38 Chromosome 17, 7675125: 7675125
13 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
14 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
15 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
16 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
17 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
18 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
19 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh38 Chromosome 17, 7674263: 7674263
20 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh37 Chromosome 17, 7577581: 7577581
21 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
22 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
23 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
24 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
25 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
26 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
27 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
28 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
29 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
30 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
31 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
32 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
33 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 GRCh37 Chromosome 13, 49039164: 49039164
34 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 GRCh38 Chromosome 13, 48465028: 48465028
35 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
36 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
37 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
38 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
39 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
43 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
44 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
45 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh38 Chromosome 3, 179218294: 179218294
46 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
47 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 GRCh38 Chromosome 17, 7675124: 7675124
48 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
49 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
50 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190

Cosmic variations for Small Cell Cancer of the Lung:

9 (show top 50) (show all 631)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6965819 XIAP lung,NS,carcinoma,non small cell carcinoma c.833C>A p.S278* 23:123886495-123886495 0
2 COSM6959777 VTCN1 lung,NS,carcinoma,non small cell carcinoma c.505G>A p.E169K 1:117153310-117153310 0
3 COSM6964908 U2AF1 lung,NS,carcinoma,non small cell carcinoma c.140C>T p.A47V 21:43100512-43100512 0
4 COSM5010415 TSC2 lung,NS,carcinoma,non small cell carcinoma c.2647C>T p.Q883* 16:2076075-2076075 0
5 COSM138991 TSC2 lung,NS,carcinoma,non small cell carcinoma c.5131G>A p.V1711M 16:2088110-2088110 0
6 COSM3591180 TP63 lung,NS,carcinoma,non small cell carcinoma c.797G>A p.R266Q 3:189866712-189866712 0
7 COSM10991 TP53 lung,NS,carcinoma,non small cell carcinoma c.396G>T p.K132N 17:7675216-7675216 0
8 COSM43896 TP53 lung,NS,carcinoma,non small cell carcinoma c.818G>C p.R273P 17:7673802-7673802 0
9 COSM10660 TP53 lung,NS,carcinoma,non small cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
10 COSM10905 TP53 lung,NS,carcinoma,non small cell carcinoma c.451C>T p.P151S 17:7675161-7675161 0
11 COSM43726 TP53 lung,NS,carcinoma,non small cell carcinoma c.727A>T p.M243L 17:7674236-7674236 0
12 COSM43911 TP53 lung,NS,carcinoma,non small cell carcinoma c.451C>A p.P151T 17:7675161-7675161 0
13 COSM43959 TP53 lung,NS,carcinoma,non small cell carcinoma c.790C>A p.L264I 17:7673830-7673830 0
14 COSM6549 TP53 lung,NS,carcinoma,non small cell carcinoma c.743G>T p.R248L 17:7674220-7674220 0
15 COSM44512 TP53 lung,NS,carcinoma,non small cell carcinoma c.740A>G p.N247S 17:7674223-7674223 0
16 COSM11205 TP53 lung,NS,carcinoma,non small cell carcinoma c.796G>C p.G266R 17:7673824-7673824 0
17 COSM10704 TP53 lung,NS,carcinoma,non small cell carcinoma c.844C>T p.R282W 17:7673776-7673776 0
18 COSM10714 TP53 lung,NS,carcinoma,non small cell carcinoma c.473G>T p.R158L 17:7675139-7675139 0
19 COSM11081 TP53 lung,NS,carcinoma,non small cell carcinoma c.733G>T p.G245C 17:7674230-7674230 0
20 COSM10656 TP53 lung,NS,carcinoma,non small cell carcinoma c.742C>T p.R248W 17:7674221-7674221 0
21 COSM10709 TP53 lung,NS,carcinoma,non small cell carcinoma c.722C>G p.S241C 17:7674241-7674241 0
22 COSM43871 TP53 lung,NS,carcinoma,non small cell carcinoma c.746G>T p.R249M 17:7674217-7674217 0
23 COSM10758 TP53 lung,NS,carcinoma,non small cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
24 COSM10663 TP53 lung,NS,carcinoma,non small cell carcinoma c.916C>T p.R306* 17:7673704-7673704 0
25 COSM43708 TP53 lung,NS,carcinoma,non small cell carcinoma c.422G>A p.C141Y 17:7675190-7675190 0
26 COSM6815 TP53 lung,NS,carcinoma,non small cell carcinoma c.461G>T p.G154V 17:7675151-7675151 0
27 COSM10992 TP53 lung,NS,carcinoma,non small cell carcinoma c.844C>G p.R282G 17:7673776-7673776 0
28 COSM10777 TP53 lung,NS,carcinoma,non small cell carcinoma c.715A>G p.N239D 17:7674248-7674248 0
29 COSM44054 TP53 lung,NS,carcinoma,non small cell carcinoma c.754C>T p.L252F 17:7674209-7674209 0
30 COSM45115 TP53 lung,NS,carcinoma,non small cell carcinoma c.640C>G p.H214D 17:7674891-7674891 0
31 COSM11564 TP53 lung,NS,carcinoma,non small cell carcinoma c.742C>G p.R248G 17:7674221-7674221 0
32 COSM11196 TP53 lung,NS,carcinoma,non small cell carcinoma c.734G>T p.G245V 17:7674229-7674229 0
33 COSM10662 TP53 lung,NS,carcinoma,non small cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
34 COSM45649 TP53 lung,NS,carcinoma,non small cell carcinoma c.854A>G p.E285G 17:7673766-7673766 0
35 COSM10645 TP53 lung,NS,carcinoma,non small cell carcinoma c.527G>T p.C176F 17:7675085-7675085 0
36 COSM44801 TP53 lung,NS,carcinoma,non small cell carcinoma c.503A>T p.H168L 17:7675109-7675109 0
37 COSM10749 TP53 lung,NS,carcinoma,non small cell carcinoma c.830G>T p.C277F 17:7673790-7673790 0
38 COSM46344 TP53 lung,NS,carcinoma,non small cell carcinoma c.341T>A p.L114* 17:7676028-7676028 0
39 COSM43687 TP53 lung,NS,carcinoma,non small cell carcinoma c.641A>G p.H214R 17:7674890-7674890 0
40 COSM43695 TP53 lung,NS,carcinoma,non small cell carcinoma c.748C>T p.P250S 17:7674215-7674215 0
41 COSM45647 TP53 lung,NS,carcinoma,non small cell carcinoma c.760A>T p.I254F 17:7674203-7674203 0
42 COSM10779 TP53 lung,NS,carcinoma,non small cell carcinoma c.818G>T p.R273L 17:7673802-7673802 0
43 COSM10889 TP53 lung,NS,carcinoma,non small cell carcinoma c.536A>G p.H179R 17:7675076-7675076 0
44 COSM44610 TP53 lung,NS,carcinoma,non small cell carcinoma c.97-2A>T p.? 17:7676274-7676274 0
45 COSM44198 TP53 lung,NS,carcinoma,non small cell carcinoma c.653T>G p.V218G 17:7674878-7674878 0
46 COSM43606 TP53 lung,NS,carcinoma,non small cell carcinoma c.734G>A p.G245D 17:7674229-7674229 0
47 COSM10672 TP53 lung,NS,carcinoma,non small cell carcinoma c.577C>T p.H193Y 17:7674954-7674954 0
48 COSM18657 TP53 lung,NS,carcinoma,non small cell carcinoma c.560-2A>G p.? 17:7674973-7674973 0
49 COSM46348 TP53 lung,NS,carcinoma,non small cell carcinoma c.1044G>T p.L348F 17:7670665-7670665 0
50 COSM10742 TP53 lung,NS,carcinoma,non small cell carcinoma c.578A>G p.H193R 17:7674953-7674953 0

Copy number variations for Small Cell Cancer of the Lung from CNVD:

7 (show top 50) (show all 515)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and in dels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and in dels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and in dels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and in dels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and in dels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rea rrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and in dels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rea rrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and in dels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rea rrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and in dels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rea rrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rea rrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and in dels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rea rrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rea rrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and in dels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rea rrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and in dels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rea rrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and in dels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rea rrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and in dels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rea rrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and in dels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rea rrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and in dels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and in dels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and in dels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and in dels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and in dels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and in dels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and in dels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and in dels small cell lung cancer
Sources

Expression for Small Cell Cancer of the Lung

About this section
Search GEO for disease gene expression data for Small Cell Cancer of the Lung.
Sources

Pathways for Small Cell Cancer of the Lung

About this section

Pathways related to Small Cell Cancer of the Lung according to KEGG:

38
# Name Kegg Source Accession
1 Small cell lung cancer hsa05222
2 MicroRNAs in cancer hsa05206

Pathways related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 38
Show member pathways
 12.8 AKT1 PIK3CA PTEN RB1 TP53
2
Pathways in cancer 38
12.77 AKT1 PIK3CA PTEN RB1 TP53
3
Gastric cancer 38
Show member pathways
 12.66 AKT1 PIK3CA PTEN RB1 TP53
4
Glioma 38
Show member pathways
 12.6 AKT1 PIK3CA PTEN RB1 TP53
5
Development HGF signaling pathway 23
Show member pathways
 12.6 AKT1 PIK3CA PTEN TP53 TP73
6
Development IGF-1 receptor signaling 23
Show member pathways
 12.31 AKT1 PIK3CA PTEN TP53
7
DNA Damage Response 1
Show member pathways
 12.29 PTEN RB1 TP53 TP73
8
Human T-cell leukemia virus 1 infection 38
12.28 AKT1 PIK3CA RB1 TP53
9
Proteoglycans in cancer 38
12.18 AKT1 MIR21 PIK3CA TP53
10
p53 Signaling 65
Show member pathways
 12.11 AKT1 PTEN RB1 TP53
11
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.02 AKT1 PIK3CA PTEN RB1 TP53
12
AKT Signaling Pathway 68
12.01 AKT1 PIK3CA PTEN TP53
13
Integrated Breast Cancer Pathway 1
12.01 AKT1 PTEN RB1 TP53
14
Direct p53 effectors 1
11.93 PTEN RB1 TP53 TP73
15
Cellular senescence (KEGG) 38
11.92 AKT1 PIK3CA PTEN RB1 TP53
16
Sphingolipid signaling pathway 38
11.87 AKT1 PIK3CA PTEN TP53
17
Glioblastoma Multiforme 65
11.8 AKT1 PTEN RB1 TP53
18
PI3K / Akt Signaling 4
11.79 AKT1 PIK3CA PTEN
19
Androgen receptor signaling pathway 1
11.79 AKT1 PTEN RB1
20
TP53 Regulates Metabolic Genes 67
11.74 AKT1 PTEN TP53
21
Glucocorticoid receptor regulatory network 1
11.72 AKT1 POMC TP53
22
Platinum drug resistance 38
11.65 AKT1 PIK3CA TP53
23
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.6 AKT1 PIK3CA RB1
24
p75(NTR)-mediated signaling 1
Show member pathways
 11.58 AKT1 PIK3CA TP53
25
Pathways Affected in Adenoid Cystic Carcinoma 1
11.52 AKT1 PIK3CA PTEN TP53
26
Central carbon metabolism in cancer 38
11.48 AKT1 PIK3CA PTEN TP53
27
PDGFR-beta signaling pathway 1
11.46 AKT1 PIK3CA PTEN
28
DNA Damage Response (only ATM dependent) 1
11.41 AKT1 PIK3CA PTEN TP53 TP73
29
Copper homeostasis 1
11.29 AKT1 PIK3CA PTEN TP53
30
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.13 AKT1 PIK3CA PTEN
31
Integrated Cancer Pathway 1
11.12 AKT1 PTEN RB1 TP53
32
Small cell lung cancer 38
10.99 AKT1 PIK3CA PTEN RB1 TP53
33
LncRNA-mediated mechanisms of therapeutic resistance 1
10.72 HOTAIR TP53
Sources

GO Terms for Small Cell Cancer of the Lung

About this section

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.77 MIR21 PTEN RB1 SST TP53
2 regulation of cell migration GO:0030334 9.65 AKT1 MIR21 SST
3 positive regulation of apoptotic process GO:0043065 9.65 AKT1 MIR21 PTEN TP53 TP73
4 regulation of signal transduction by p53 class mediator GO:1901796 9.61 AKT1 TP53 TP73
5 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.5 MIR21 PTEN RB1
6 negative regulation of macroautophagy GO:0016242 9.49 AKT1 PIK3CA
7 anoikis GO:0043276 9.46 AKT1 PIK3CA
8 negative regulation of cell size GO:0045792 9.4 AKT1 PTEN
9 cellular response to decreased oxygen levels GO:0036294 9.16 AKT1 PTEN
10 protein kinase B signaling GO:0043491 9.13 AKT1 PIK3CA PTEN
11 cellular response to hypoxia GO:0071456 8.92 AKT1 MALAT1 PTEN TP53
Sources

Sources for Small Cell Cancer of the Lung

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....